The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Concepta announces first myLotus® pregnancies

14 May 2019 07:00

RNS Number : 8856Y
Concepta PLC
14 May 2019
 

 

 

 

Concepta announces first myLotus® pregnancies

 

Concepta Plc (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market with a primary focus on women's fertility and hormone health announces today its first pregnancies and user testimonials for the myLotus® monitor and app.

 

myLotus® the revolutionary home based, self-test product was launched in the UK in November 2018 with early 'trying to conceive' users providing personal video feedback and testimonials on their menstrual cycle hormone changes and profile ('signatures') enabling women to better understand their menstrual cycle and fertility journey (www.mylotus.com). In March the Company announced its first supply agreement with Boots UK (part of Walgreens Boots Alliance).

 

User testimonials from pregnancy users included;

 

"MyLotus couldn't have been a better purchase if it tried. From the moment I came across it on instagram it just made so much sense to buy. Having been told it could possibly be a harder route for me to fall pregnant, I wanted something I could trust to help me and something which made total sense. MyLotus easily explains all the different features of how to use it, and the fact that it produces an individualised LH level for each ovulation test is quite frankly genius. This allowed me to track my ovulation in such a concise way that I felt in safe hands. The app is an added bonus which uses your data to inform you when you should be taking a pregnancy test and stores all your test results if you ever need to look back over or show your doctor. We fell pregnant within our first cycle of using MyLotus and I feel passionately that this was purely down to it. My average LH levels were quite low so only MyLotus would have been able to catch my spike using the numerical factor. The added bonus of MyLotus was the 9 pregnancy tests the pack comes with, which I happily used every single one to quadruple check I really was pregnant :)" Isabel. (London)

"Myself and my partner are in our late 30s and decided we wanted to start trying for children. We tried the normal vitamin supplements and over the counter ovulation tests but after 18 months had not conceived. As reasonably healthy people we knew age was a factor, so decided to try the lotus fertility monitor as a more specific aid for ovulation. It's an easy monitor to set up and use and importantly is very specific to you, your cycle and hormone levels and the support from customer care (in what can be an anxious time) is excellent, I could not rate it more highly. We liked that the monitor shows the exact level of LH in urine so you can tell exactly (I mean exactly) when your peak is. This is why it is miles above any other fertility aids. After just two months of using the monitor we had the lovely news that we are now expecting a baby. Good health management and the correct vitamins is very important, but I feel we can put our success down to lotus and their support. Please get a hold of one, and don't lose hope. Ever! With love to all the couples trying." Naomi. (Scotland)

 

myLotus® empowers women to self-test their personalised hormone levels and identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app available in iOS and Android formats via the www.mylotus.com website.

 

myLotus® is available to women who are planning to start a family or for those who have previously struggled to naturally conceive, enabling couples an alternative prior to considering more costly IVF treatment. The Company expects to release further hormone health and wellbeing tests to complement its fertility offering later this year.

 

Matthew Walls, Chairman said: "We are extremely proud and delighted for our first user pregnancies. We have waited patiently for our pregnancies to sufficiently progress before we released this sensitive and important news. We understand the difficulties and emotions involved in trying to conceive and look forward to supporting all our users on their pregnancy journey."

 

Enquiries

Company: www.conceptaplc.com, Product: www.mylotus.com

Matthew Walls, Chairman

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin

Tel: +44 (0)20 368 3550

 

Novum Securities

Colin Rowbury

+44 (0) 20 7399 9400

 

About Concepta Plc:

Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

 

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

 

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

 

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAXSDFFXNEFF
Date   Source Headline
3rd Jul 20159:29 amRNSHolding(s) in Company
30th Jun 201511:21 amRNSProposed Settlement of Director Debt
30th Jun 201510:49 amRNSResult of AGM and Capital Reorganisation
9th Jun 20151:09 pmRNSOperational Update: Namibia
4th Jun 20151:26 pmRNSNotice of AGM and Proposed Capital Reorganisation
2nd Jun 20157:00 amRNSOperational update Oman
1st Jun 20157:00 amRNSConditional Subscription Update
22nd May 20154:29 pmRNSConditional Subscription
18th May 201512:00 pmRNSResult of General Meeting
28th Apr 201511:10 amRNSConditional Subscription - Posting of Circular
7th Apr 20157:00 amRNSFinal results year ended 31 December 2014
2nd Apr 20157:00 amRNSOperational Update: Sultanate of Oman
17th Mar 20155:36 pmRNSConditional Share Subscription
8th Jan 20157:00 amRNSOperational Update
31st Dec 201410:49 amRNSTotal Voting Rights
13th Nov 20147:00 amRNSBoard Changes, Subscription and Issue of Equity
28th Oct 20147:00 amRNSOperational Update
28th Oct 20147:00 amRNSAppointment of Geological Advisor
27th Oct 20141:18 pmRNSHolding(s) in Company
17th Sep 20145:28 pmRNSAppointment of Joint Broker
10th Sep 20147:00 amRNSInterim Results
31st Jul 20144:45 pmRNSTotal Voting Rights
22nd Jul 201410:48 amRNSOperational Update: Namibia
4th Jul 20146:08 pmRNSHolding(s) in Company
4th Jul 201412:54 pmRNSHolding(s) in Company
27th Jun 20143:17 pmRNSResult of AGM
27th Jun 20147:00 amRNSPlacing
26th Jun 20142:00 pmRNSPreliminary unaudited results
24th Jun 201411:08 amRNSAGM
16th May 20147:00 amRNSOperational Update: Sultanate of Oman
24th Mar 20147:00 amRNSFarm-out Update: Namibia and Zambia
11th Mar 20145:34 pmRNSBoard Change
4th Feb 20147:00 amRNSOperational Update: Namibia
29th Jan 201411:49 amRNSHolding(s) in Company
29th Jan 20147:00 amRNSOperational Update: Namibia
27th Jan 20149:24 amRNSCompletion of Equity Swap and Payment Acceleration
19th Dec 20137:00 amRNSAppointment of Joint Broker
11th Nov 20137:00 amRNSCorporate Activities Update
22nd Oct 20133:29 pmRNSGrant of Options and Opening of London Office
25th Sep 20137:00 amRNSInterim Results for the six months to 30 June 2013
23rd Sep 20137:00 amRNSOperational Update: Zambia
16th Sep 20137:00 amRNSOperational Update: Sultanate of Oman
9th Sep 20137:00 amRNSOperational Update: Namibia
31st Jul 20137:00 amRNSOperational Update: Namibia
23rd Jul 20137:00 amRNSOperational Update: Zambia
16th Jul 20137:00 amRNSAppointment of Exploration Manager
5th Jul 20137:00 amRNSAdmission and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.